Clinical trials: Carcinoid
Carcinoid Tumor, Metastatic Carcinoid Tumor
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary…
- Conditions
- Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Neoplasm
- Trial name
- NCT02399215
- Testing
- Laboratory Biomarker Analysis, Nintedanib, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoid Tumors
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Sunitinib may provide an opportunity for a novel therapeutic strategy for the treatment of subjects with neuroendocrine tumors.
- Trial name
- SUNLAND (NCT01731925)
- Testing
- Lanreotide, Sunitinib
- Where
- 20 sites in Belgium, France
- Volunteers
- 44 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Carcinoid Heart Disease
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of Carcinoid Heart Disease and progression of…
- Trial name
- CRUSOE-NETs (NCT03498040)
- Testing
- Study of the occurrence of Carcinoid Heart Disease
- Where
- 19 sites in France
- Volunteers
- 670 people
- Sponsor
- Hospices Civils de Lyon
Pheochromocytoma, Paraganglioma
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much…
- Conditions
- Pheochromocytoma, Paraganglioma, Carcinoid
- Trial name
- NCT00339131
- Testing
- Ultratrace iobenguane I 131
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Caregiver, Lobectomy Patient
Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers
This trial studies whether a telephone-based physical activity intervention before and after lung cancer surgery can be provided to older patients and their caregivers.
- Conditions
- Caregiver, Lobectomy Patient, Lung Carcinoid Tumor, Lung Non-Small Cell Carcinoma
- Trial name
- NCT04085081
- Testing
- E-mail, Exercise Intervention, Quality-of-Life Assessment
- Volunteers
- healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Carcinoid Tumor, Malignant Carcinoid Syndrome
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid…
- Trial name
- RADIANT-2 (NCT00412061)
- Testing
- Octreotide, Everolimus
- Where
- 70 sites in United States, Australia and 13 more
- Volunteers
- 429 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Tumors
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Study evaluating SOM230 in patients with metastatic carcinoid tumors
- Trial name
- NCT00088595
- Testing
- Pasireotide (SOM230)
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg)…
- Trial name
- NETTER-1 (NCT01578239)
- Testing
- Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 231 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas
68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET
In gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs), radical surgery provides good long-term outcome and low recurrence rates.
- Conditions
- Neuroendocrine Tumor Carcinoid, Neuroendocrine Tumor of Pancreas, Gep Net
- Trial name
- RGS-GEP-NET (NCT05448157)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- European Institute of Oncology
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with advanced neuroendocrine tumors who have failed standard treatment or are…
- Trial name
- NCT02455596
- Testing
- Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Lung Cancer, Metastatic Cancer
Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Cryotherapy kills tumor cells by freezing them. This may be an effective treatment for primary lung cancer or lung metastases that cannot be removed by surgery.
- Trial name
- NCT00303901
- Testing
- cryosurgery, positron emission tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Melanoma, Soft Tissue Sarcoma
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.
- Conditions
- Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung
- Trial name
- NCT00580320
- Testing
- Dacarbazine and bortezomib
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University
Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing…
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma
- Trial name
- NCT00093782
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Neuroendocrine Tumor
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
The goal of this clinical trial is to investigate if chemotherapy works with surufatinib to treat pulmonary neuroendocrine tumors. It will also learn about the safety of this combination regimen.
- Trial name
- NCT07357623
- Testing
- Surufatinib Combined With Standard chemotherapy, Surufatinib
- Where
- 4 sites in China
- Volunteers
- 96 people
- Sponsor
- Shanghai Chest Hospital
Carcinoid Syndrome
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
- Trial name
- TELEPATH (NCT02026063)
- Testing
- Telotristat etiprate
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 124 people
- Sponsor
- Lexicon Pharmaceuticals
Bladder Cancer, Breast Cancer
Docetaxel in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American…
- Conditions
- Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00003565
- Testing
- docetaxel
- Where
- 74 sites in United States, Canada and 1 more
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- ACTION-1 (NCT05477576)
- Testing
- RYZ101, Everolimus, Sunitinib
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- RayzeBio, Inc.
Carcinoid Syndrome, Carcinoid
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome.
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- NCT05361668
- Testing
- Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 36 people
- Sponsor
- Crinetics Pharmaceuticals Inc.